Octahydrocurcumin, a final hydrogenated metabolite of curcumin, possesses superior anti-tumor activity through induction of cellular apoptosis
- 7 March 2018
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 9 (4) , 2005-2014
Abstract
Curcumin (CUR), a promising natural-occurring dietary compound for the treatment of hepatocellular carcinoma (HCC), was closely associated with its metabolite.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province (2014A030310475)
This publication has 40 references indexed in Scilit:
- Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerizationProceedings of the National Academy of Sciences, 2012
- p53 Dynamics Control Cell FateScience, 2012
- Malignant ascites: pathophysiology and treatmentInternational Journal of Clinical Oncology, 2012
- Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal NeoplasiaCancer Prevention Research, 2011
- Curcuminoids activate p38 MAP kinases and promote UVB‐dependent signalling in keratinocytesExperimental Dermatology, 2010
- Epidemiology of hepatocellular carcinoma in JapanJournal of Gastroenterology, 2009
- Bcl-2 family proteins and cancerOncogene, 2008
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- Inhibitory Effects of Curcumin and Tetrahydrocurcuminoids on the Tumor Promoter‐induced Reactive Oxygen Species Generation in Leukocytes in vitro and in vivoJapanese Journal of Cancer Research, 1998
- Mdm2 promotes the rapid degradation of p53Nature, 1997